183 related articles for article (PubMed ID: 16988580)
21. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate and Pralatrexate.
Wood GS; Wu J
Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
[TBL] [Abstract][Full Text] [Related]
23. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
24. Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.
Casanova M; Medina-Pérez A; Moreno-Beltran M; Mata-Vazquez M; Rueda A
Ther Clin Risk Manag; 2011; 7():401-8. PubMed ID: 22076116
[TBL] [Abstract][Full Text] [Related]
25. Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.
McGuire JJ; Haile WH
Biochem Pharmacol; 2009 Apr; 77(7):1161-72. PubMed ID: 19174154
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.
Kang MH; Harutyunyan N; Hall CP; Papa RA; Lock RB
Br J Haematol; 2009 May; 145(3):389-93. PubMed ID: 19298590
[TBL] [Abstract][Full Text] [Related]
27. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA
Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785
[TBL] [Abstract][Full Text] [Related]
28. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
[TBL] [Abstract][Full Text] [Related]
29. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
O'Connor OA; Amengual J; Colbourn D; Deng C; Sawas A
Leuk Lymphoma; 2017 Nov; 58(11):2548-2557. PubMed ID: 28738754
[TBL] [Abstract][Full Text] [Related]
30. Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.
Altınay S; Kural A; Özmen A; Tural D; Tutar Y
Anticancer Agents Med Chem; 2023; 23(3):298-305. PubMed ID: 35692151
[TBL] [Abstract][Full Text] [Related]
31. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.
Foss FM; Parker TL; Girardi M; Li A
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e445-e447. PubMed ID: 30181105
[No Abstract] [Full Text] [Related]
32. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Marchi E; O'Connor OA
Ther Adv Hematol; 2012 Aug; 3(4):227-35. PubMed ID: 23606933
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
[TBL] [Abstract][Full Text] [Related]
34. The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
Visentin M; Unal ES; Zhao R; Goldman ID
Cancer Chemother Pharmacol; 2013 Sep; 72(3):597-606. PubMed ID: 23881211
[TBL] [Abstract][Full Text] [Related]
35. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
Kelly KR; Gabrail N; Weitman S; Sarantopoulos J; Olszanski AJ; Edenfield W; Venitz J; Reddy G; Yang A; Hasal SJ; Lockhart AC
Cancer Chemother Pharmacol; 2016 Nov; 78(5):929-939. PubMed ID: 27638045
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.
Ho AL; Lipson BL; Sherman EJ; Xiao H; Fury MG; Apollo A; Seetharamu N; Sima CS; Haque S; Lyo JK; Sales R; Cox L; Pfister DG
Invest New Drugs; 2014 Jun; 32(3):549-54. PubMed ID: 24566705
[TBL] [Abstract][Full Text] [Related]
38. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Serova M; Bieche I; Sablin MP; Pronk GJ; Vidaud M; Cvitkovic E; Faivre S; Raymond E
Br J Cancer; 2011 Jan; 104(2):272-80. PubMed ID: 21179031
[TBL] [Abstract][Full Text] [Related]
39. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.
Marneros AG; Grossman ME; Silvers DN; Husain S; Nuovo GJ; MacGregor-Cortelli B; Neylon E; Patterson M; O'Connor OA; Zain JM
Blood; 2009 Jun; 113(25):6338-41. PubMed ID: 19389878
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma.
Rodd AL; Ververis K; Karagiannis TC
Clin Med Insights Oncol; 2012; 6():305-14. PubMed ID: 23032692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
